Today I am looking at the growth prospects of two FTSE 100 big hitters.
The prescription for healthy returns
At first glance pharma giant AstraZeneca (LSE: AZN) may be one of the last FTSE 100 plays to be considered irresistible to growth seekers.
Thanks to the relentless top-line pressure caused by patent expirations across key labels, AstraZeneca has seen earnings recede during each of the past three years. And the City does not expect things to improve any time soon a marginal dip this year is forecasted to be followed with a 6% fall in 2016.
And the London-based firm faces additional hurdles down the line as exclusivity on stomach acid treatment Nexium ran out this year, and cholesterol battler Crestor is due to lose patent protection in 2016.
Still, I am confident that AstraZenecas reinvented product pipeline combined with galloping emerging market healthcare investment will provide the ammunition to get the bottom-line firing again. The business currently has its eyes on gaining approval for between eight and ten new drugs by the end of next year alone.
On top of this, AstraZeneca remains busy on the M&A trail in highly-lucrative areas, aimed at bolstering its promising pipeline still further. Just today the business announced the purchase of Takeda Pharmaceuticals respiratory operations for $575m, and the firm is also weighing up a deal to acquire Dutch cancer specialists Acerta Pharma.
With AstraZeneca trading on a very reasonable P/E rating of 16.8 times for 2016, I reckon now could be a great time to invest in the medicine firms exciting growth prospects.
Stick a star in your trolley
I believe that electronics and white goods retailer Dixons Carphone (LSE: DC) should also see earnings surge in the coming years thanks to steadily-improving conditions on the UK High Street. Britons are enjoying steadily-fattening wallets thanks to persistently-low inflation, rising wages and improving employment levels, and I reckon these factors should continue driving sales for some time to come.
Dixons Carphone cheered the market in midweek business as it released its latest set of interims. The London-based company saw revenues advance 5% higher between May and October, a result that blasted pre-tax profit 23% higher to 121m. Consequently the gadget specialists hiked the interim dividend by almost a third to 3.25p per share.
Despite the impact of intense market competition and adverse currency effects across its foreign businesses, Dixons Carphones ability to grab market share in all its major territories allowed it to enjoy chunky sales growth in the period. With the hard work of last years merger of Dixons Retail and Carphone Warehouse now largely completed, I believe performance should continue to pick up in the months and years ahead.
The number crunchers expect earnings at Dixons Carphone to shoot 6% higher in the 12 months to April 2016, and an extra 11% bounce is predicted for the following year. I reckon a P/E rating of 16.8 times provides great value given the firms excellent upward momentum.
But whether or not you share my bullish take on AstraZeneca or Dixons Carphone, I strongly recommend you check out this special Fool report that identifies what I believe is one of the best growth stocks money can buy.
Our BRAND NEW “A Top Growth Share From The Motley Fool” report looks at a brilliant FTSE 250 stock that has already delivered stunning shareholder returns, and whose sales are expected to top the magic 1 billion marker in the coming years, according to the Fool’s crack team of analysts.
Click here to enjoy this exclusive ‘wealth report’ — it’s 100% free and comes with no obligation.
Royston Wild has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca. We Fools don’t all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.
